-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
- Inhibikase Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$4.96M, a 14.2% increase year-over-year.
- Inhibikase Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$18.4M, a 3.4% increase year-over-year.
- Inhibikase Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$19M, a 5.4% decline from 2022.
- Inhibikase Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.1M, a 22.1% decline from 2021.
- Inhibikase Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.8M, a 419% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)